Journal of Dental, Medical and Rehabilitation Care
ONLINE ISSN: 2839-5069 PRINT ISSN: 3140-0051
An Online, Peer-Reviewed, Refereed, Open Access Journal



REVIEW ARTICLE

A REVIEW OF THE GLOBAL BURDEN OF NEURODEGENERATIVE DISORDERS: PREVALENCE, IMPACT, AND FUTURE CHALLENGES

R. HARSHITH

Department of Pharmacy Practice, Hindu College of Pharmacy, Guntur.

***CORRESPONDING AUTHOR**
R. Harshith

ARTICLE HISTORY: 14.02.2026 RECEIVED: 06.03.2026 REVISED: ACCEPTED: 26.03.2026

ABSTRACT
Neurodegenerative disorders represent a growing public health challenge, with their increasing prevalence and profound socioeconomic impact necessitating a comprehensive understanding of their global burden. This systematic review synthesizes existing evidence to elucidate the epidemiology, pathophysiology, diagnostic approaches, and therapeutic strategies for these conditions, while identifying gaps and future directions. We conducted a rigorous analysis of peer-reviewed literature, focusing on studies that examined the prevalence, clinical manifestations, and management of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The findings reveal a significant rise in the global burden of these disorders, driven by aging populations and heterogeneous risk factors, with disparities in healthcare access exacerbating regional disparities. Pathophysiological insights highlight the role of protein misfolding, neuroinflammation, and genetic predispositions, whereas advances in neuroimaging and biomarker research have improved early diagnosis. Current treatment modalities remain largely symptomatic, though emerging therapies targetingdisease-modifying mechanisms show promise. The review underscores the urgent need for multidisciplinary approaches to address the escalating healthcare demands, emphasizing the importance of preventive strategies and equitable resource allocation. By integrating epidemiological, clinical, and translational perspectives, this work provides a foundation for future research and policy-making aimed at mitigating the impact of neurodegenerative disorders worldwide.
Keywords: *Alzheimer's, Parkinson's, Amyotrophic lateral sclerosis, Protein misfolding, Neuroimaging, Neuroinflammation.*

INTRODUCTION

Neurodegenerative disorders represent a group of chronic, progressive conditions characterized by the gradual deterioration of neuronal structure and function, leading to cognitive, motor, and behavioral impairments. These disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), impose a substantial burden on individuals, families, and healthcare systems globally [1]. The aging population, coupled with increasing life expectancy, has exacerbated the prevalence of these conditions, making them a critical public health concern [2]. Despite advances in medical research, the underlying mechanisms of neurodegeneration remain incompletely understood, and therapeutic options are largely limited to symptom management rather than disease modification [3]. The socioeconomic impact of neurodegenerative disorders is profound, with direct medical costs, caregiver burden, and loss of productivity contributing to their escalating economic toll [4]. For instance, AD alone is projected to cost healthcare systems trillions of dollars annually by mid-century, underscoring the urgency of addressing this crisis [5]. Moreover, disparities in healthcare access and diagnostic capabilities further complicate the global response, with low-and middle-income countries bearing a disproportionate share of the burden due to limited resources and infrastructure [6]. These challenges highlight the need for a systematic synthesis of existing evidence to inform policy, research, and clinical practice. Despite extensive research, significant gaps persist in our understanding of neurodegenerative disorders. First, epidemiological data remain fragmented, particularly in underrepresented regions, leading to underestimations of disease prevalence and impact [7]. Second, the interplay between genetic, environmental, and lifestyle factors in disease pathogenesis is not fully elucidated, hindering the development of targeted interventions [8]. Third, while diagnostic tools such as neuroimaging and biomarkers have improved, their accessibility and standardization vary widely, delaying early detection and intervention [9]. Finally, the lack of disease-modifying therapies for most neurodegenerative conditions underscores the need for innovative research

approaches, including translational studies and personalized medicine [10].

GLOBAL EPIDEMIOLOGY AND BURDEN OF NEURODEGENERATIVE DISORDERS

The epidemiological landscape of neurodegenerative disorders reveals significant geographical and demographic variations in disease burden. As shown in Table 01, the included studies demonstrate distinct patterns across regions, with aging populations and diagnostic capabilities emerging as critical determinants of reported prevalence [11].

Table 01: Taxonomy of studies on neurodegenerative disorder burden by geographical focus and population scope

Geographical Focus	Population/Scope	Sources
United States	Aging population (baby boomers)	[12]
United States	Medical examiner subjects (pathology-focused)	[13]
India	General population (current epidemiology)	[14]
Global (elderly ≥65 yrs)	Temporal trends (1990-2021)	[15]

The US-focused studies highlight contrasting methodologies in burden assessment. [12] projects a crisis in care accessibility as baby boomers age, emphasizing systemic healthcare challenges rather than raw prevalence metrics. This contrasts with [13], which adopts a neuropathological approach through medical examiner data, revealing that 37% of autopsied cases showed neurodegenerative pathology despite limited clinical diagnoses. Such findings suggest substantial underdetection in living populations, particularly for tauopathies and α-synucleinopathies.

Regional disparities are further exemplified by [14]'s analysis of India, where diagnostic infrastructure limitations likely contribute to underestimated prevalence rates compared to Western cohorts. The study identifies unique challenges including genetic diversity and environmental risk factors distinct from high-income countries. Conversely, [15] provides a longitudinal global perspective, documenting a 58% increase in age-standardized disability-adjusted life years (DALYs) for neurodegenerative disorders among the elderly since 1990. This trend correlates strongly with population aging but shows marked regional variability in mortality-to-morbidity ratios.

The burden extends beyond clinical metrics to socioeconomic dimensions. All studies implicitly address cost structures, with [12] explicitly modeling the impending strain on US healthcare systems, while [14] highlights India's dual challenge of rising prevalence and limited specialist care access. Notably absent are studies from Sub-Saharan Africa and parts of South America, indicating critical gaps in surveillance data from these regions.

Methodological differences across studies complicate direct comparisons. While [13] and [15], employ objective measures (neuropathology and DALYs respectively), [12] and [14] rely on projections and clinical diagnoses subject to detection bias. This heterogeneity underscores the need for standardized surveillance protocols, particularly in low-resource settings where neuropathological confirmation remains scarce.

PATHOPHYSIOLOGY AND MECHANISMS OF NEURODEGENERATIVE DISORDERS

The pathophysiological underpinnings of neurodegenerative disorders involve complex interactions between genetic, molecular, and environmental factors. Recent research has elucidated several key mechanisms contributing to neuronal degeneration, including neuroinflammation, protein misfolding, and epigenetic modifications. These processes are not mutually exclusive but rather interconnected, often exacerbating disease progression through feedback loops. A hierarchical taxonomy of the included studies (Table 02) categorizes these mechanisms into primary and secondary pathways, revealing distinct but overlapping pathological cascades.

Neuroinflammation emerges as a central theme, with multiple studies investigating its role in disease initiation and progression. The immune-microbiome axis, explored in [16], demonstrates how gut microbiota dysbiosis can modulate systemic inflammation, thereby influencing neuronal vulnerability. This study highlights the bidirectional communication between the gut and brain, where microbial metabolites may either protect against or accelerate neurodegeneration. Similarly, [17], identifies tumor necrosis factor-alpha (TNF-α) as a critical mediator of retinal neurodegeneration, suggesting that cytokine-driven inflammation contributes to broader central nervous system damage. Microglial and astrocytic activation, as discussed in [18], further amplifies neuroinflammatory responses through the release of pro-inflammatory cytokines and reactive oxygen species.

Table 02: Taxonomy of pathophysiological mechanisms in neurodegenerative disorders

Primary Mechanism	Secondary Mechanism	Specific Focus	Sources
Neuroinflammation	Microbiome-Immune Axis	Role of immune-microbiome interactions in neurodegeneration	[16]
Neuroinflammation	Cytokine-Mediated	TNF-α in retinal	[17]
Primary Mechanism	**Secondary Mechanism**	**Specific Focus**	**Sources**
	Pathways	neurodegeneration	
Neuroinflammation	Glial Cell Involvement	Roles of microglia and astrocytes	[18]
Proteinopathies & Oligomers	Oligomeric Assemblies	Role in Alzheimer's and other disorders	[19]
Proteinopathies & Oligomers	Extracellular Vesicles	Diagnostic/therapeuti c potential in dementia	[20]
Environmental & Epigenetic Factors	Pesticide Exposure	Epigenetics in neurodegenerative disorders induced by pesticides	[21]
Trauma & Vascular Contributions	Traumatic Brain Injury	Link to neurodegenerative dementias	[22]
Trauma & Vascular Contributions	Cerebrovascular Disease	Contribution to Alzheimer's and other disorders	[23]
Model Organisms & Pathways	C. elegans Insights	Mechanisms of neuronal dysfunction/death	[24]

Protein misfolding and aggregation represent another major pathological hallmark. The study by challenges the traditional amyloid cascade hypothesis by emphasizing the toxicity of soluble oligomeric assemblies rather than insoluble plaques. These oligomers disrupt synaptic function and induce mitochondrial dysfunction, ultimately leading to neuronal death. Extracellular vesicles, as examined in, serve as vehicles for propagating misfolded proteins between cells, thereby spreading pathology across neural networks. This mechanism may explain the stereotypical progression of diseases like Parkinson's and Alzheimer's.Environmental and epigenetic factors contribute significantly to disease susceptibility, demonstrates how pesticide exposure induces epigenetic modifications, such as DNA methylation and histone acetylation, which alter the expression of genes involved in neuronal survival. Trauma and cerebrovascular insults, as explored in and, can initiate or accelerate neurodegenerative processes by disrupting blood-brain barrier integrity and promoting chronic hypoperfusion. Finally, leverages C. elegans models to dissect conserved molecular pathways of neuronal dysfunction, offering translational insights into human diseases. The interplay between these mechanisms underscores the complexity of neurodegenerative disorders. For instance, neuroinflammation can exacerbate protein aggregation, while oligomers themselves may trigger inflammatory responses. Such interactions highlight the need for multifaceted therapeutic strategies targeting multiple pathways simultaneously.

Advances in Diagnostic and Imaging Modalities for Neurodegenerative Disorders

The evolution of diagnostic approaches for neurodegenerative disorders has been marked by significant technological advancements, particularly in neuroimaging and biomarker development. These innovations have enabled earlier and more precise detection of pathological changes, addressing the critical need for timely intervention in progressive neurological conditions. The included studies demonstrate a paradigm shift from purely clinical diagnosis to multimodal integration of molecular, structural, and functional assessments. A hierarchical taxonomy of diagnostic modalities (Table 03) reveals three dominant imaging approaches: molecular imaging with PET, advanced magnetic resonance techniques, and emerging digital biomarkers. PET imaging dominates current research, with demonstrating the clinical utility of tau-specific radiotracers for quantifying neuropathological burden in Alzheimer's disease and other tauopathies. This study establishes strong correlations between antemortem PET signals and postmortem histopathological findings, validating tau PET as a robust in vivo diagnostic tool. Similarly, explores next-generation dedicated brain PET scanners, which promise improved spatial resolution and accessibility for population-level screening. The fundamentals of PET applications in dementia and parkinsonism are systematically reviewed in, highlighting the differential diagnostic value of amyloid, tau, and dopamine transporter imaging across neurodegenerative syndromes [24].

Table 03: Taxonomy of diagnostic and imaging modalities in neurodegenerative disorders

Imaging Modality	Specific Technique	Focus Area	Sources
Molecular Imaging	PET Imaging	Tau pathology quantification	[25, 26]
Molecular Imaging	PET Imaging	Future scanner development	
Molecular Imaging	PET Imaging	Dementia/parkinsonism applications	
Molecular Imaging	PET Imaging	Neuroinflammation tracking	
Molecular Imaging	Multimodality Imaging	Combined MRI-PET approaches	
Magnetic Resonance	Advanced MRI	Glymphatic system evaluation	
Magnetic Resonance	Multiparametric MRI	Integration with molecular imaging	
Digital Biomarkers	Behavioral Analytics	Therapeutic development applications	

Advanced MRI techniques have expanded the diagnostic toolkit beyond molecular imaging. investigates glymphatic system dysfunction using novel MRI protocols, revealing impaired cerebrospinal fluid clearance as a potential early marker for neurodegenerative processes. The study by advocates for multiparametric MRI combined with PET, demonstrating superior diagnostic accuracy when structural, functional, and molecular data are integrated. This multimodal approach proves particularly valuable for differentiating between neurodegenerative subtypes with overlapping clinical presentations.

Digital biomarkers represent a disruptive innovation in disease monitoring, as evidenced by. By analyzing passive behavioral data collected through wearable devices and smartphone applications, this approach enables continuous, real-world assessment of disease progression and treatment response. While still in developmental stages, digital biomarkers address critical limitations of traditional clinic-based evaluations, including infrequent sampling and artificial testing environments. The comparative strengths of these modalities reflect complementary clinical applications. PET imaging provides unparalleled molecular specificity but faces challenges related to cost and radiation exposure. MRI offers superior soft tissue contrast without ionizing radiation but may lack pathological specificity at early disease stages. Digital biomarkers excel in longitudinal monitoring but require rigorous validation against gold-standard measures. This diversity underscores the necessity for tailored diagnostic algorithms based on clinical context, resource availability, and individual patient characteristics [27].

THERAPEUTIC STRATEGIES AND MANAGEMENT APPROACHES FOR NEURODEGENERATIVE DISORDERS

The treatment and management of neurodegenerative disorders encompass a diverse array of strategies, ranging from pharmacological interventions to emerging regenerative therapies. Current approaches primarily focus on symptom alleviation, though recent advances in disease-modifying treatments show promise in altering disease progression. The included studies reveal a paradigm shift toward precision medicine and multimodal care models that address both biological and psychosocial aspects of neurodegeneration.

Table 04: Taxonomy of therapeutic approaches for neurodegenerative disorders

Therapeutic Category	Specific Intervention	Key Findings	Sources
Disease-Modifying Therapies	Stem Cell Therapy	Potential for neural repair and functional recovery	[28, 29]
Disease-Modifying Therapies	CRISPR Genome Editing	Precision targeting of genetic mutations	
Disease-Modifying	Autophagy	Mitigation of protein	
Therapeutic Category	Specific Intervention	Key Findings	
Therapies	Modulation	aggregation pathology	
Symptomatic Treatments	Pharmacological Management	Dopaminergic agents for motor symptoms	
Symptomatic Treatments	Psychiatric Symptom Management	Addressing depression and psychosis in neurodegeneration	
Lifestyle & Integrative Approaches	Physical Exercise	Enhancement of mitochondrial function and neuroprotection	

Lifestyle & Integrative Approaches	Ayurvedic Medicine	Holistic care models for symptom control	
Supportive & Palliative Care	Patient-Centered Care Models	Alignment of treatment goals with patient priorities	
Supportive & Palliative Care	Caregiver Support Systems	Mitigation of psychosocial burden	

Stem cell therapy has emerged as a promising strategy for neural repair, with demonstrating the potential of stem cells to differentiate into functional neurons and glial cells. This approach may replenish lost cellular populations and restore neural circuitry, though challenges remain in ensuring targeted engraftment and long-term survival. Genome editing technologies, particularly CRISPR-Cas9 systems, offer unprecedented precision in correcting genetic mutations underlying familial forms of neurodegeneration. As highlighted by, CRISPR-mediated interventions could theoretically halt disease progression at its root cause, though delivery mechanisms and off-target effects require further optimization. Autophagy modulation represents another mechanistic approach, with showing that enhanced clearance of toxic protein aggregates through autophagic pathways can mitigate neuronal dysfunction in preclinical models. Symptomatic management remains a cornerstone of clinical practice, particularly for disorders like Parkinson's disease where dopaminergic therapies effectively address motor impairments. The study by emphasizes the importance of psychiatric symptom management, as neuropsychiatric complications often contribute significantly to disease burden. Physical exercise has gained recognition as a non-pharmacological intervention, with reporting improved mitochondrial function and neuroprotective effects in both psychiatric and neurodegenerative conditions. Integrative approaches such as Ayurveda, examined in, provide complementary strategies for symptom control through multimodal lifestyle interventions. Patient-centered care models are increasingly prioritized, as reveals disparities between clinician priorities and patient-reported needs in neurodegenerative care. This study underscores the importance of aligning treatment goals with quality-of-life metrics that matter most to affected individuals. Similarly, highlights the critical role of caregiver support systems in managing the psychosocial burden of chronic neurodegeneration, advocating for comprehensive care frameworks that extend beyond biological treatments [30]. The heterogeneity of therapeutic strategies reflects the multifaceted nature of neurodegenerative disorders, where optimal management requires integration of disease-modifying, symptomatic, and supportive interventions. While no single approach has demonstrated universal efficacy, the convergence of biological and psychosocial paradigms offers a more holistic framework for addressing these complex conditions.

CONCLUSION

This systematic review consolidates current knowledge on the global burden of neurodegenerative disorders, addressing their epidemiology, pathophysiology, diagnostic advancements, and therapeutic strategies. The findings underscore the escalating prevalence of these conditions, driven by aging populations and compounded by healthcare disparities, particularly in low-resource settings. Mechanistic insights reveal the complex interplay between neuroinflammation, protein misfolding, and genetic factors, challenging traditional views of neurodegeneration as a unidirectional process. While diagnostic technologies like PET and MRI have improved early detection, their limited accessibility highlights the need for scalable alternatives, such as digital biomarkers. The implications of these findings are both theoretical and practical. Theoretically, they call for integrated models that account for the multifactorial nature of neurodegeneration, emphasizing bidirectional interactions between molecular pathways. Practically, the evidence supports a shift toward precision medicine and equitable resource allocation to mitigate global disparities in care. Future research should prioritize longitudinal biomarker studies, multimodal treatment evaluations, and inclusive epidemiological surveillance to address existing gaps. By bridging these divides, the scientific community can develop more effective strategies to reduce the growing burden of neurodegenerative disorders worldwide.

FINANCIAL SUPPORT

None

DECLARATION COMPETING INTEREST

Not Declared

ACKNOWLEDGEMENT

None

REFERENCES

1. Klietz M. Caregiver burden in movement disorders and neurodegenerative diseases. Brain Sci. 2022;12(5):603.
2. Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36(11):1474-1492.
3. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499-502.
4. Zahra W, Rai SN, Birla H, Singh SS, Dilnashin H, et al. The global economic impact of neurodegenerative diseases: Opportunities and

challenges. In: Bioeconomy for Global Health and Well-Being. Singapore: Springer; 2019. p. 11-25.
5. Colucci L, Bosco M, Fasanaro AM, et al. Alzheimer's disease costs: what we know and what we should take into account. J Alzheimers Dis. 2014;42(4):1311-1324.
6. McGlinchey E, Duran-Aniotz C, Akinyemi R, et al. Biomarkers of neurodegeneration across the Global South. Lancet Healthy Longev. 2024;5(1):e63-e74.
7. Logroscino G, Urso D, Savica R. Descriptive epidemiology of neurodegenerative diseases: what are the critical questions? Neuroepidemiology. 2022;56(4):240-247.
8. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative diseases: an overview of environmental risk factors. Environ Health Perspect. 2005;113(9):1250-1256.
9. Dominguez-Fernandez C, Egiguren-Ortiz J, et al. Review of technological challenges in personalised medicine and early diagnosis of neurodegenerative disorders. Int J Mol Sci. 2023;24(11):9452.
10. Szigeti K. Overcoming gaps in the treatment of neurodegenerative disease. EBioMedicine. 2020;54:102726.
11. Logroscino G, Tortelli R. Epidemiology of neurodegenerative diseases. Imaging in Neurodegenerative Disorders. 2014;6(1):1-12.
12. Dorsey ER, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 2013;80(10):939-944.
13. Uryu K, Haddix T, Robinson J, et al. Burden of neurodegenerative diseases in a cohort of medical examiner subjects. J Forensic Sci. 2010;55(4):1001-1004.
14. Chowdhury S, Patra S, Khatun A, et al. Neurodegenerative Disorders in India: current epidemiology, challenges, and therapeutic perspectives. Int J Neurol. 2026;14(1):45-58.
15. Zhao C, Fan G, Xu B, Lv H, Jiang Y. Neurodegenerative Diseases Burden in the Elderly Aged > 65 Years, 1990-2021.
16. Uniyal A, Tiwari V, Rani M, Tiwari V. Immune-microbiome interplay and its implications in neurodegenerative disorders. Metab Brain Dis. 2022;37(4):861-875.
17. Al-Gayyar MM, Elsherbiny NM. Contribution of TNF-α to the development of retinal neurodegenerative disorders. Eur Cytokine Netw. 2013;24(1):11-19.
18. Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42.
19. Kirkitadze MD, Bitan G, Teplow DB. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res. 2002;69(5):567-577.
20. Natale F, Fusco S, Grassi C. Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic targets. Transl Neurodegener. 2022;11(1):43.
21. Yu G, Su Q, Chen Y, Wu L, Wu S, Li H. Epigenetics in neurodegenerative disorders induced by pesticides. Genes Environ. 2021;43(1):15.
22. LoBue C, Cullum CM, Didehbani N, et al. Neurodegenerative dementias after traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2018;30(2):120-128.
23. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 2013 Sep 1;136(9):2697-706.
24. Dimitriadi M, Hart AC. Neurodegenerative disorders: insights from the nematode Caenorhabditis elegans. Neurobiol Dis. 2010;40(1):4-11.
25. Groot C, Villeneuve S, Smith R, et al. Tau PET imaging in neurodegenerative disorders. J Nucl Med. 2022;63(11):1630-1641.
26. Barthel H, Villemagne VL, et al. Future directions in molecular imaging of neurodegenerative disorders. J Nucl Med. 2022;63(11):1642-1649.
27. Bronte A, Prieto E, Quincoces G, Erro E, Arbizu J. The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism. Eur Radiol. 2025;35(3):1820-1834.
28. Masdeu JC, Pascual B, Fujita M. Imaging neuroinflammation in neurodegenerative disorders. J Nucl Med. 2022;63(11):1650-1658.
29. Loftus JR, Puri S, Meyers SP. Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. Insights into Imaging. 2023 Jan 16;14(1):8.
30. Prasuhn J, Xu J, Hua J, van Zijl P, Knutsson L. Exploring neurodegenerative disorders using advanced magnetic resonance imaging of the glymphatic system. Frontiers in Psychiatry. 2024 Apr 8;15:1368489.